• Home
  •  / Ionis Pharmaceuticals

Ionis Pharmaceuticals

OverviewSuggest Edit

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The Company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients.

TypePublic
Founded1989
HQCarlsbad, USMap
Websiteionispharma.com
View Jobs (46)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)737(+35%)
Job Openings46
Revenue (FY, 2018)$599.7 M(+19%)
Share Price (Jan 2020)$59.1

Key People/Management at Ionis Pharmaceuticals

Stanley Crooke

Stanley Crooke

CEO
Lynne Parshall

Lynne Parshall

COO / CFO
Elizabeth Hougen

Elizabeth Hougen

Chief Accounting Officer
C. Frank Bennett

C. Frank Bennett

Senior Vice President of Research
Sarah Boyce

Sarah Boyce

CBO
Steve Hughes

Steve Hughes

Chief Clinical Development Officer
Show more

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, US (HQ)
2855 Gazelle Ct
Show all (1)

Ionis Pharmaceuticals Financials and Metrics

Ionis Pharmaceuticals Revenue

Ionis Pharmaceuticals's revenue was reported to be $599.67 m in FY, 2018
USD

Revenue (Q3, 2019)

167.9m

Gross profit (Q3, 2019)

166.9m

Gross profit margin (Q3, 2019), %

99.4%

Net income (Q3, 2019)

26.2m

EBIT (Q3, 2019)

2.5m

Market capitalization (27-Jan-2020)

8.3b

Closing stock price (27-Jan-2020)

59.1

Cash (30-Sept-2019)

247.9m

EV

8.7b
Ionis Pharmaceuticals's current market capitalization is $8.3 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

108.5m99.1m102.0m147.3m214.2m283.7m346.6m507.7m599.7m

Revenue growth, %

45%32%22%

Cost of goods sold

1.8m

Gross profit

597.9m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

23.5m28.6m21.1m24.8m20.7m23.2m47.3m11.6m43.4m38.1m23.6m28.2m57.1m44.1m62.6m120.4m49.1m36.9m38.5m110.9m110.3m104.2m120.9m144.4m117.7m145.4m297.2m163.8m167.9m

Cost of goods sold

1.0m1.4m967.0k

Gross profit

296.2m162.4m166.9m

Gross profit Margin, %

100%99%99%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

70.1m65.5m124.5m160.0m143.0m128.8m84.7m129.6m278.8m

Accounts Receivable

51.1m

Prepaid Expenses

7.1m5.4m8.7m7.5m15.7m14.8m72.3m102.5m

Inventories

7.5m8.6m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

46.0m100.1m86.2m85.0m55.3m56.4m85.6m84.6m107.7m296.5m256.4m161.8m94.1m73.2m148.3m119.5m126.6m93.3m112.5m84.3m114.2m133.0m159.2m227.5m805.5m479.9m375.8m272.5m247.9m

Prepaid Expenses

7.0m6.3m7.4m7.6m7.6m7.4m5.7m7.8m8.1m5.8m7.4m9.8m8.6m8.4m13.2m29.9m29.1m17.4m17.3m15.2m25.9m51.5m48.9m62.1m77.0m97.1m98.7m102.1m118.8m

Inventories

8.4m11.1m19.4m

Current Assets

536.9m507.6m437.4m410.7m377.1m347.6m350.4m361.6m431.8m669.1m763.3m722.1m705.8m681.2m835.4m855.5m868.3m763.9m698.0m730.3m962.4m964.4m1.1b1.1b2.1b2.1b2.4b2.4b2.4b
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(61.3m)(84.8m)(65.5m)(60.6m)(39.0m)(88.3m)(86.6m)(17.3m)215.0m

Depreciation and Amortization

4.8m6.6m7.1m6.6m6.4m7.0m7.5m6.7m12.5m

Inventories

284.0k(1.7m)(2.0m)(1.9m)1.7m(609.0k)(590.0k)(2.5m)1.4m

Accounts Payable

1.3m875.0k1.3m66.0k4.8m9.2m(10.7m)1.8m(655.0k)
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(34.8m)(47.3m)(20.0m)(37.9m)(64.8m)(24.0m)(25.2m)(62.8m)(1.7m)(11.8m)(31.3m)(43.4m)(70.0m)(16.7m)18.9m(16.8m)(62.9m)(119.8m)(112.4m)3.5m(7.7m)(12.6m)(10.8m)(67.4m)(87.7m)90.9m80.9m99.3m

Depreciation and Amortization

1.6m3.1m4.8m1.6m3.4m5.2m1.8m3.7m5.6m2.0m4.0m6.1m2.4m4.9m7.7m3.5m7.2m10.5m

Inventories

496.0k257.0k948.0k(549.0k)(492.0k)(293.0k)379.0k(769.0k)(2.4m)688.0k985.0k(962.0k)922.0k915.0k1.6m(2.5m)(5.7m)(6.6m)

Accounts Payable

(2.6m)2.0m1.4m(2.7m)(8.2m)862.0k(11.4m)(12.4m)(15.2m)472.0k(10.0m)(1.7m)(13.1m)(14.2m)(13.6m)(17.2m)(16.1m)(18.8m)
show all
USDY, 2019

EV/EBIT

3.5 k x

EV/CFO

128.7 x

Financial Leverage

1.9 x
Show all financial metrics

Ionis Pharmaceuticals Online and Social Media Presence

Ionis Pharmaceuticals's Trends

Embed Graph

Ionis Pharmaceuticals News and Updates

October 29, 2019

What Caused The Sell-Off In Ionis Pharmaceuticals Stock?

Ionis Pharmaceuticals (NASDAQ: IONS), a pharma company engaged in discovering and developing RNA-targeted therapeutics, has seen its stock decline by about 11% over the last week, trading at levels of around $55 currently. The decline is possibly due to a delay in the release of data...
October 22, 2019

Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast

CARLSBAD, Calif., Oct. 22, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business...
June 06, 2019

Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders

CARLSBAD, Calif., June 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Stanley T. Crook, M.D., Ph.D., chairman of the board and chief executive officer, will present a general corporate update and 30-year retrospective in conjunction with its 2019...
February 13, 2019

Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast

CARLSBAD, Calif., Feb. 13, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress. Interested ...
January 02, 2019

Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT...
December 20, 2018

Ionis Pharmaceuticals outlines CEO succession plan

Ionis Pharmaceuticals Inc. said late Thursday that Brett Monia will succeed Stanley Crooke as chief executive in a year. The drug development company said Monia, who is the current chief operating officer, will become CEO in January 2020, and Crooke will become executive chairman of Ionis's board. …
Show more

Ionis Pharmaceuticals Blogs

January 10, 2020

Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy Jonathan.Lorin… Fri, 01/10/2020 - 07:01 Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx i…
January 09, 2020

Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer

Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer Content Import Thu, 01/09/2020 - 07:05 Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer January 9, 2020 at 7:05 AM EST This rel…
January 07, 2020

/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./

/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ Content Import Tue, 01/07/2020 - 12:15 /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ January 7, 2020 at 7:05 AM EST This release is a backfill from a News Wire General In th…
January 07, 2020

Ionis' neurological franchise marks year of achievement

- Potential breakthrough therapies for Huntington's, Alzheimer's, ALS and Parkinson's among numerous programs advancing in the clinic - Neurological R&D team received several prestigious honors - Advances in neurological research highlighted in leading peer-reviewed journals CARLSBAD, Calif. , J…
January 06, 2020

Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif. , Jan. 6, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview at the 38 th annual J.P.
January 02, 2020

New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease william.meady@… Thu, 01/02/2020 - 08:01 New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp…
Show more

 Ionis Pharmaceuticals Frequently Asked Questions

  • When was Ionis Pharmaceuticals founded?

    Ionis Pharmaceuticals was founded in 1989.

  • Who are Ionis Pharmaceuticals key executives?

    Ionis Pharmaceuticals's key executives are Stanley Crooke, Lynne Parshall and Elizabeth Hougen.

  • How many employees does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 737 employees.

  • What is Ionis Pharmaceuticals revenue?

    Latest Ionis Pharmaceuticals annual revenue is $599.7 m.

  • What is Ionis Pharmaceuticals revenue per employee?

    Latest Ionis Pharmaceuticals revenue per employee is $813.7 k.

  • Who are Ionis Pharmaceuticals competitors?

    Competitors of Ionis Pharmaceuticals include Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals and Regulus Therapeutics.

  • Where is Ionis Pharmaceuticals headquarters?

    Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.

  • Where are Ionis Pharmaceuticals offices?

    Ionis Pharmaceuticals has an office in Carlsbad.

  • How many offices does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 1 office.